Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shun Lu

Showing results (21-30 of 703) with videos related to

Pageof 71
Sort By:
Lancet (London, England)|March 21, 2026
PD-L1, treatment intensity, and outcomes in squamous NSCLC - Authors' replyZhiwei Chen, Shun Lu
The Oncologist|March 2, 2019
Immuno-Oncology in ChinaShun Lu, Bruce A Chabner
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|January 30, 2013
Maintenance Therapy for NSCLC: Consensus and ControversyShun Lu, Yong-Feng Yu
World Journal of Clinical Oncology|October 11, 2014
Acetylcholine receptor pathway in lung cancer: New twists to an old storyXiao-Min Niu, Shun Lu
The New England Journal of Medicine|October 23, 2024
Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC. ReplyShun Lu, Suresh S Ramalingam
The Oncologist|March 2, 2019
Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint InhibitorsShun Lu, Yongfeng Yu, Yi Yang
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|August 20, 2010
[Genome wide association study on lung cancer.]Xiaomin Niu, Xinghao Ai, Shun Lu
Translational Lung Cancer Research|March 14, 2022
Tagrisso incremental therapy in a case of meningeal metastasis of lung cancer with EGFR mutation: a case reportYingjia Sun, Xinghao Ai, Shun Lu
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|February 12, 2011
[Advances in multimodality therapy of lung cancer]Xinghao Ai, Shun Lu, Meilin Liao
Science China. Life Sciences|April 19, 2020
Effectiveness of PD-1/PD-L1 inhibitors in the treatment of lung cancer: Brightness and challengeYing Yang, Yongfeng Yu, Shun Lu
Pageof 71

Showing results (21-30 of 703) with videos related to

Sort By:
Pageof 71
Lancet (London, England)|March 21, 2026
PD-L1, treatment intensity, and outcomes in squamous NSCLC - Authors' replyZhiwei Chen, Shun Lu
The Oncologist|March 2, 2019
Immuno-Oncology in ChinaShun Lu, Bruce A Chabner
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|January 30, 2013
Maintenance Therapy for NSCLC: Consensus and ControversyShun Lu, Yong-Feng Yu
World Journal of Clinical Oncology|October 11, 2014
Acetylcholine receptor pathway in lung cancer: New twists to an old storyXiao-Min Niu, Shun Lu
The New England Journal of Medicine|October 23, 2024
Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC. ReplyShun Lu, Suresh S Ramalingam
The Oncologist|March 2, 2019
Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint InhibitorsShun Lu, Yongfeng Yu, Yi Yang
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|August 20, 2010
[Genome wide association study on lung cancer.]Xiaomin Niu, Xinghao Ai, Shun Lu
Translational Lung Cancer Research|March 14, 2022
Tagrisso incremental therapy in a case of meningeal metastasis of lung cancer with EGFR mutation: a case reportYingjia Sun, Xinghao Ai, Shun Lu
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|February 12, 2011
[Advances in multimodality therapy of lung cancer]Xinghao Ai, Shun Lu, Meilin Liao
Science China. Life Sciences|April 19, 2020
Effectiveness of PD-1/PD-L1 inhibitors in the treatment of lung cancer: Brightness and challengeYing Yang, Yongfeng Yu, Shun Lu
Pageof 71